AnalyzeDirect

Analyze Publications Database

Dose-finding quantitative FDG PET imaging study with the oral pan-AKT inhibitor GSK2141795 in patients with gynecological malignancies

Hatice Gungor, Azeem Saleem, Syed Babar, Roberto Dina, Mona El-Bahrawy, Ed Curry, Nona Rama, Michele Chen, Emily Pickford, Roshan Agarwal, Sarah Blagden, Sabin Carme, Cristian Salinas, Sam J Madison, Elizabeth C Krachey, Ademi Santiago-Walker, Deborah A Smith, Shannon R Morris, Euan A Stronach, and Hani Gabra. Dose-finding quantitative FDG PET imaging study with the oral pan-AKT inhibitor GSK2141795 in patients with gynecological malignancies. J Nucl Med published ahead of print October 1, 2015

Publication Date
October 2015

How Analyze was Used
“Tumor and normal regions of interest (ROI) on PET-CT were defined on the summated
PET images using Analyze® software and applied to the dynamic images to obtain radioactivity
versus time curves, which were normalized for injected radioactivity.”

Keywords
Molecular Imaging
Oncology: GU
PET
AKT
FDG-PET
GSK2141795
Ovarian Cancer

Author Affiliation(s)
Imperial College London, United Kingdom. (Hatice Gungor, Roberto Dina, Mona El-Bahrawy, Ed Curry, Nona Rama, Michele Chen, Emily Pickford, Roshan Agarwal, Sarah Blagden, Euan A Stronach, and Hani Gabra.)

Imanova Centre for Imaging Sciences, United Kingdom. (Azeem Saleem and Cristian Salinas)

Imperial College Healthcare NHS Trust, United Kingdom. (Syed Babar)

AVIESAN, France. (Sabin Carme)

GlaxoSmithKline, United States. (Sam J Madison, Elizabeth C Krachey, Ademi Santiago-Walker, and Deborah A Smith)

MedImmune (AstraZeneca), United States. (Shannon R Morris)

ID# 3195

Tags: , ,